Wegovy: where to consult the official leaflet and what to review
Let's be clear. If you've made it this far, you're probably looking for the official Wegovy leaflet or want to ensure you're reading the correct information for your dose.
What this page is and what it is not intended to be
This is not a product sheet or a summary for making decisions on your own. Wegovy is a prescription-only medicine containing semaglutide, and its use should be understood within the approved indication and relevant professional monitoring. The idea here is for you to find the correct official leaflet, not to settle for a simplified or decontextualised version.
Where to consult the official Wegovy leaflet
It is best to open the official leaflet in CIMA according to the exact presentation shown on your packaging or in your prescription. For Wegovy, CIMA offers different access points by dose:
- Wegovy 0.25 mg — official leaflet
- Wegovy 0.5 mg — official leaflet
- Wegovy 1 mg — official leaflet
- Wegovy 1.7 mg — official leaflet
- Wegovy 2.4 mg — official leaflet
As institutional support, the EMA maintains the EPAR sheet and a product information document that integrates the leaflet for the different authorised concentrations.
What presentation to identify before opening the leaflet
Before reading anything, it's a good idea to check what presentation appears exactly on your packaging. In the official documentation consulted, FlexTouch presentations of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg appear, with differences in volume and commercial status depending on the entry. This detail is important because it prevents confusing instructions, storage or package data with a different pen.
What to review in the leaflet and why a quick summary is not enough
The official leaflet itself structures the information very clearly: what Wegovy is and what it is used for, what you need to know before starting to use it, how to use it, possible side effects, storage and contents of the package. In addition, the consolidated EMA version includes the leaflet for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg.
Settling for a quick summary is usually a bad idea because it omits important nuances: for whom it is indicated, what precautions should be reviewed, when to consult if problems arise, and what use of the medicine makes no sense.
When to consult a healthcare professional
You should consult a doctor, pharmacist or nurse if you have doubts about whether the presentation matches your packaging, if you are using other medicines, if you have a history that could change the assessment of the treatment, or if side effects that concern you appear during use. The leaflet itself insists on this professional consultation and reminds that it should not be used as a substitute for an individual assessment.
You may also be interested in reading about Ozempic official leaflet and semaglutide and weight management.
